Search

439 results for "lecanemab".

Research summaries 393

Showing the best 200 of 393, 61–70, page 7 of 20. Filter these by subject, year and score in the research library →

1. Lifetime cost-effectiveness of lecanemab for early Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/lifetime-cost-effectiveness-of-lecanemab-for-early-alzheimer-s-disease-41694525

   The incremental cost of the lecanemab group compared to the aducanumab group was $30,018.97, with an increase in quality-adjusted life-years (QALYs) of 0.25, resulting in an ICER of $121,678.49 per QALY gained. The result of the …

2. Safety and effectiveness of the anti-amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspectiveResearch summary

   Research summaries · alzhub.org/study/safety-and-effectiveness-of-the-anti-amyloid-monoclonal-antibody-mab-40051090

   … antibodies, such as lecanemab, provides a promising novel treatment pathway with potential disease-modifying effects for patients with early Alzheimer's disease (AD). Lecanemab, which gained marketing approval by the United …

3. Safety of Lecanemab After 6‐Month Treatment in the DIAN‐TU‐001 TrialResearch summary

   Research summaries · alzhub.org/study/safety-of-lecanemab-after-6month-treatment-in-the-diantu001-trial-41447712

   Lecanemab was generally well-tolerated during the 6-month lecanemab-only treatment period. Overall, 80.4% of the 97 participants enrolled and treated experienced an adverse event. The most common AEs were ARIA-H (26.8%), headache …

4. The Cost-Effective Price of Lecanemab for Patients with Early Alzheimer's Disease in SwedenResearch summary

   Research summaries · alzhub.org/study/the-cost-effective-price-of-lecanemab-for-patients-with-early-40730714

   … cost-effective price for lecanemab for treating early Alzheimer's disease in Sweden from the perspective of formal care payers. Methods We developed a Markov model with states defined by disease severity and care setting. The …

5. The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effectResearch summary

   Research summaries · alzhub.org/study/the-higher-benefit-of-lecanemab-in-males-compared-to-females-in-39887549

   Introduction The phase 3 trial CLARITY AD found lecanemab slowed cognitive decline by 27%. However, subgroup analyses indicated a significant 31% sex difference in the effect and suggested no or limited effectiveness in females. …

6. Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future researchResearch summary

   Research summaries · alzhub.org/study/use-of-lecanemab-and-donanemab-in-the-canadian-healthcare-system-39893139

   Lecanemab and donanemab are monoclonal antibody therapies that remove amyloid-beta from the brain. They are the first therapies that alter a fundamental mechanism, amyloid-beta deposition, in Alzheimer disease (AD). To inform …

7. [Pathophysiology and Clinical Presentation of Amyloid-Related Imaging Abnormality Induced by Anti-Amyloid-β Antibody Lecanemab]Research summary

   Research summaries · alzhub.org/study/pathophysiology-and-clinical-presentation-of-amyloid-related-imaging-39935267

   Lecanemab, the first monoclonal antibody drug targeting amyloid beta (Aβ), was approved for slowing the progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in the United States and …

8. ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/aria-in-patients-treated-with-lecanemab-ban2401-in-a-phase-2-study-in-36949897

   Introduction Lecanemab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity at amyloid plaques. Amyloid-related imaging abnormalities …

9. Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/amyloid-solutions-lecanemab-gantenerumab-and-donanemab-in-the-2abd646d

   … disease trajectory. Lecanemab’s selective affinity for protofibrillar Aβ disrupts early neurotoxic aggregates, providing a proactive approach for mitigating synaptic dysfunction. Donanemab, by targeting pyroglutamate-modified …

10. Lecanemab bei Alzheimer-Krankheit: Frühe Therapie ist sicherResearch summary

    Research summaries · alzhub.org/study/lecanemab-bei-alzheimer-krankheit-fruhe-therapie-ist-sicher-eac9be64

    … monoklonalen Antikörper Lecanemab bei Patientinnen und Patienten mit früher symptomatischer Alzheimer-Krankheit. Publication History Article published online: 02 December 2025 © 2025. Thieme. All rights reserved. Georg Thieme …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-13. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.